Please login to the form below

Not currently logged in
Email:
Password:

CTCL

This page shows the latest CTCL news and features for those working in and with pharma, biotech and healthcare.

Almirall eyes $62m takeover of multicytokine specialist Bioniz

Almirall eyes $62m takeover of multicytokine specialist Bioniz

for cutaneous T-cell lymphoma (CTCL). ... BNZ-1 a selective and simultaneous inhibitor of cytokines IL-2, IL-9 and IL-15 which is in early-stage testing for CTCL and also has potential for alopecia areata,

Latest news

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    Takeda, for example, used EQ- 5D in its Adcetris programme despite doubts about whether the measure was sensitive enough to show the therapy’s effect on cutaneous T-cell lymphoma (CTCL) ... However, those and other limitations are unlikely to last

  • Pharma deals in August 2015 Pharma deals in August 2015

    30600. Therakos. Mallinckrodt. Approved cell therapy platform for the palliative treatment of cutaneous T‐cell lymphoma [CTCL].

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    387. Ceptaris Therapeutics / Actelion. Acquisition. Valchlor for mycosis fungoides-type CTCL (NDA). ... CTCL = cutaneous T-cell lymphoma. VLP  = virus-like particle produced in plant expression systems .

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...